Table 1.
DNA vaccines against ZIKV infection.
| Vaccine’s Name or Component | Immunogenicity in the Induction of Immune Responses | Animal Model | Vaccine Doses | Administration Route | Virus Challenged | Ref. |
|---|---|---|---|---|---|---|
| prM and E | Completely protected mice against ZIKV-associated damage to the testes and sperm and prevented viral persistence in the testes | Type-I interferon knockout mice | Two doses at two-week interval | i.m. | Puerto Rico Strain PRVABC59 | [17] |
| pVAX1-ZME (prM and E) | Induced robust ZIKV-specific cellular and long-term humoral immune responses with high and sustained neutralizing activity, which provided passive protection against ZIKV infection in neonatal mice | BALB/c mice | Three doses at three-week intervals | i.m. | (SMGC-1 strain, GenBank accession number: KX266255 |
[18] |
| GLS-5700 (prM and E) | Prevented fertility loss in male IFNAR−/− mice | C57BL/6J mice and IFNAR−/− mice | Two doses at two-week interval | i.m. | Puerto Rico Strain PRVABC59 | [19] |
| VRC5288 and VRC5283 | Induced detectable T-cell response and antibody response with neutralization activity. The immunogenicity of VRC5283 was better than that of VRC5288. | Humans | Single dose, two and three doses | i.m | No | [20] |
| prM and E | Elicited protective responses against multiple diverse ZIKV isolates | C57BL/6c mice | Four doses at days 0, 24, 42, and 199 | i.m | Puerto Rico Strain PRVABC59 | [21] |
| pVAX-NS1, pVAX-tpaNS1, pVAX-tpaNS1-IMX313P (NS1) | pVAX-tpaNS1 vaccination induced significantly higher NS1-specific antibody titers and CD4+, as well as CD8+, T-cell responses compared to pVAX-NS1 and pVAX-tpaNS1- IMX313P | BALB/c and IFNAR−/− mice | Three doses at two-week intervals | i.d. | ZIKVzkv2015 | [22] |
Note: prM, anterior membrane; E, envelope; IFNAR−/−, type I IFN receptor–deficient; i.m., intramuscular injection; i.d., intradermal injection.